Trials / Completed
CompletedNCT02770157
Efficacy and Safety of DA-3002 in Short Children Borns SGA.
Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Short Children Born Small for Gestational Age.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 4 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin® in short children born small for gestational age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-3002 | |
| DRUG | Genotropin® |
Timeline
- Start date
- 2016-02-26
- Primary completion
- 2019-08-28
- Completion
- 2019-08-28
- First posted
- 2016-05-12
- Last updated
- 2019-10-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02770157. Inclusion in this directory is not an endorsement.